5-year Follow-up of a Randomized Controlled Trial of Immediate versus Delayed Zoledronic Acid for Prevention of Bone Loss in Postmenopausal Women with Breast Cancer Starting Letrozole after Tamoxifen: N03CC (Alliance)
      QxMD      Google Scholar   
Citation:
Cancer vol 121 (15) 2537-2543
Year:
2015
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Long-Term-Followup
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
4
Parents:
None
Children:
None
Program:
CCP
Primary Committee:
Symptom Inter
Sec. Committees:
   
Pharmas:
 
Grants:
N01 CA035431, U10 CA035269, CA-37404, U10 CA031946, U10 CA033601, U10 CA037404, U10 CA180821, CA-35103, CA-25224, UG1 CA189823, P30 CA015083, U10 CA035415, CA-35415, U10 CA035431, UG1 CA189808, CA-35269, U10 CA025224, U10 CA035103  
Corr. Author:
 
Authors:
                     
Networks:
KS055, LAPS-MD017, LAPS-MN026, PR028   
Study
NCCTG-N03CC
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
zoledronic acid, bone loss, postmenopausal, breast cancer, letrozole, tamoxifen